PURPOSE: DNA methylation plays an important role in thyroid oncogenesis. The aim of this study was to investigate the connection between global and local DNA methylation status and to establish the levels of important DNA methylation regulators (TET

Human papillomavirus (HPV) infection is the leading cause of cervical cancer. The Papanicolaou cytology test is the usually employed type of screening for this infection; however, its sensibility is limited. Only a small percentage of women infected with high‑risk HPV develop cervical cancer with an array of genetic and epigenetic modifications. Thus, it is necessary to develop rapid, reproducible and minimally invasive technologies for screening. DNA methylation has gained attention as an alternative method for molecular diagnosis and prognosis in HPV infection. The aim of the present review was to highlight the potential of DNA methylation in cervical neoplasia screening for clinical applications. It was observed that the methylation human and viral genes was correlated with high‑grade lesions and cancer. Methylation biomarkers have shown a good capacity to discriminate between high‑grade lesions with a transformative potential and cervical cancer, being able to detect these modifications at an early stage. With further research, the epigenetic profiles and subtypes of the tumors could be elaborated, which would aid in therapy selection by opening avenues in personalized precision medicine. Response to therapy could also be evaluated through such methods and the accessibility of liquid biopsies would allow a constant monitoring of the patient's status without invasive sampling techniques.

Three novel Co(II) complexes of the type [Co(C₄H₅O₂)₂L₂] (where C₄H₅O₂ is methacrylate anion; L = C₃H₄N₂ (imidazole; HIm) (1), C₄H₆N₂ (2-methylimidazole; 2-MeIm) (2), C₅H₈N₂ (2-ethylimidazole; 2-EtIm) (3)) have been synthesized and characterized by elemental analysis, IR and UV-Vis spectroscopic techniques, thermal analysis and single crystal X-ray diffraction. X-ray crystallography revealed for complexes (1) and (2) distorted trigonal bipyramid stereochemistry for Co(II), meanwhile for complex (3) evidenced that the unit cell comprises three molecular units with interesting structural features. In each unit, both stereochemistry adopted by metallic ion and coordination modes of carboxylate anions are different. The screening of antimicrobial activity revealed that Candida albicans planktonic cells were the most susceptible, with minimal inhibitory concentration (MIC) values of 7.8 μg/mL for complexes (1) and (2) and 15.6 μg/mL for complex (3). Complexes (1) and (2) proved to be more active than complex (3) against the tested bacterial strains, both in planktonic and biofilm growth state, with MIC and minimal biofilm eradication concentration (MBEC) values ranging from 15.6 to 62.5 μg/mL, the best antibacterial effects being noticed against Staphylococcus aureus and Pseudomonas aeruginosa. Remarkably, the MBEC values obtained for the four tested bacterial strains were either identical or even lower than the MIC ones. The cytotoxicity assay indicated that the tested complexes affected the cellular cycle of HeLa, HCT-8, and MG63 cells, probably by inhibiting the expression of vimentin and transient receptor potential canonical 1 (TRPC1). The obtained biological results recommend these complexes as potential candidates for the development of novel anti-biofilm agents.

BACKGROUND : Thyroid carcinoma is the most common endocrine malignancy worldwide. Changes in DNA methylation can cause silencing of normally active genes, especially tumour suppressor genes (TSG) or activation of normally silent genes. OBJECTIVE : Th

(1) Background: Cervical cancer is a significant health concern, with the main cause being persistent infection with high-risk Human Papillomavirus (hrHPV). There is still no evidence for why viral persistence occurs in some women, but recent studies have revealed the interplay between cervical microbiota and hrHPV. This research aimed to characterize the cervicovaginal microbiota in cervical lesion progression and HPV infection status. (2) Methods: This study included 85 cervical specimens from women from the north-eastern region of Romania. DNA was isolated from cervical secretion for HPV genotyping and 16S ribosomal RNA gene NGS sequencing. (3) Results: Our study revealed a distinct pattern within the studied group when considering Lactobacillus species, which differs from findings reported in other populations. Specifically, the presence of Lactobacillus iners coupled with the absence of Lactobacillus crispatus alongside Atopobium spp., Prevotella spp., and Gardnerella spp. could serve as defining factors for severe cervical lesions. The results also showed a significant association between microbiota diversity, HPV infection, and cervical lesion progression. (4) Conclusions: As the microbiota profile seems to vary among different populations and individuals, a deeper comprehension of its composition has the potential to develop personalized detection and treatment approaches for cervical dysplasia and cancer.

Background: Cervical cancer remains a major global health challenge, ranking fourth among malignancies in women, with an estimated 660,000 new cases and 350,000 deaths in 2022. Despite advances in vaccination and screening, incidence and mortality remain disproportionately high in low- and middle-income countries. The disease is strongly linked to persistent infection with high-risk human papillomavirus (HPV) types, predominantly HPV 16 and 18, whose E6 and E7 oncoproteins drive cervical intraepithelial neoplasia (CIN) and invasive cancer. This review summarizes current evidence on clinically relevant biomarkers in HPV-associated CIN and cervical cancer, emphasizing their role in screening, risk stratification, and disease management. Methods: We analyzed the recent literature focusing on validated and emerging biomarkers with potential clinical applications in HPV-related cervical disease. Results: Biomarkers are essential tools for improving early detection, assessment of progression risk, and personalized management. Established markers such as p16 immunostaining, p16/Ki-67 dual staining, and HPV E6/E7 mRNA assays increase diagnostic accuracy and reduce overtreatment. Prognostic indicators, including squamous cell carcinoma antigen (SCC-Ag) and telomerase activity, provide information on tumor burden and recurrence risk. Novel approaches—such as DNA methylation panels, HPV viral load quantification, ncRNAs, and cervico-vaginal microbiota profiling—show promise in refining risk assessment and supporting non-invasive follow-up strategies. Conclusions: The integration of validated biomarkers into clinical practice facilitates more effective triage, individualized treatment decisions, and optimal use of healthcare resources. Emerging biomarkers, once validated, could further improve precision in predicting lesion outcomes, ultimately reducing the global burden of cervical cancer and improving survival.